[the prevalence of metabolic]{.smallcaps} disorders has increased dramatically in the last few decades, particularly in developed and developing countries. Changes in lifestyle, diet, and physical activity---although contributing to this epidemic---do not explain the rapid increase in incidence. The importance of nutrient exposure before birth and postnatally in increasing the risk of metabolic disease in later life has been highlighted in a number of epidemiological studies ([@B2], [@B15]). With the number of overweight and obese women of child-bearing age increasing worldwide, this presents a worrying picture of a cyclical, transgenerational transmission of obesity. Models of maternal obesity have been developed to understand the mechanisms contributing to the programming of obesity in these offspring, which could result in intervention, treatment, or prevention.

The development of obesity often results in the onset of further metabolic complications, including insulin resistance and cardiovascular disease, together termed the metabolic syndrome. The hepatic manifestation of the metabolic syndrome ([@B20]), nonalcoholic fatty liver disease (NAFLD), is the most common liver disease in the Western hemisphere with prevalence as high as 30% ([@B19]). Features of metabolic syndrome in adult offspring, including NAFLD, have been observed in several animal models of maternal diet-induced obesity ([@B4], [@B23], [@B28]).

A number of pathogenic mechanisms for NAFLD have been suggested; however, a clear and consistent model of etiology has yet to be elucidated. Hepatic lipid deposition is predominantly attributed to dysregulated lipid homeostasis, which can result from increased fatty acid delivery from adipose tissue, increased synthesis of fatty acid via de novo lipogenesis, decreased mitochondrial β-oxidation, or a combination of these ([@B25]). The relative importance of each factor is likely to differ under different metabolic states ([@B9], [@B10]). NAFLD is also associated with insulin resistance, which is thought to be central to its pathogenesis ([@B20]). However, as obesity is a strong predictor of insulin resistance, it confounds the investigation of underlying mechanisms.

Oxidative stress has been suggested as a possible trigger for the onset of both insulin resistance and hepatic steatosis ([@B8], [@B29]). Studies have shown extensive association between oxidative stress markers and obesity, insulin resistance, and diabetes through interference of insulin signaling ([@B13], [@B26], [@B39]). Upregulation of pathways for reactive oxygen species (ROS) production and oxidative stress in insulin-responsive tissues (liver and adipose tissue) has been observed before the onset of insulin resistance ([@B22]), which could be suppressed by dietary restriction or antioxidant supplementation ([@B5], [@B7], [@B16]). Further, oxidative stress markers and inflammatory gene expression have been reported in the placenta of obese diabetic pregnancies ([@B30]), suggesting a role for oxidative stress in providing an abnormal developmental environment in offspring, which may lead to adverse metabolic effects.

In this study, we aimed to investigate the mechanisms underlying the onset of NAFLD in the offspring of diet-induced obese mice. To date, animal studies investigating the effects of maternal overnutrition on metabolic disease in offspring have studied offspring at 3 mo of age and older. By 3 mo of age, however, body weights have already diverged with offspring of obese dams being heavier and fatter than controls, thus confounding the investigation of underlying mechanisms ([@B4], [@B24], [@B28]). Therefore, we chose to study a time point prior to differences in offspring adiposity---8 wk of age---to investigate the etiology of hepatic steatosis in response to maternal diet-induced obesity. This gave us a better insight into uncoupling the interaction between multiple mechanistic factors contributing to the pathogenesis of NAFLD. Given the accumulating evidence of the importance of de novo lipogenesis in contributing to hepatic lipid deposition and the implications of oxidative stress in the onset of insulin resistance and hepatic steatosis in animal models, we also investigated these mechanisms in contributing to NAFLD onset in our nutritional programming model.

MATERIALS AND METHODS {#sec1}
=====================

 {#sec1-1}

### Animal model. {#sec1-1-1}

All studies were approved by the local Ethics Committee and were conducted according to the Home Office Animals (Scientific Procedures) Act 1986. Primiparous female C57BL/6J mice were fed ad libitum either a standard chow RM1 diet \[∼7% simple sugars, 3% fat, 50% polysaccharide, 15% protein (wt/wt), 10.74 kJ/g\] or a semisynthetic energy-rich highly palatable obesogenic diet \[∼10% simple sugars, 20% animal lard, 28% polysaccharide, 23% protein (wt/wt), 28.43 kJ/g\] supplemented with sweetened condensed milk (Nestle, UK) (∼16% fat, 33% simple sugars, 15% protein, 13.7 kJ/g) and fortified with mineral and vitamin mix AIN93G. Both diets were purchased from Special Dietary Services (Witham, UK). After 6 wk on the diets, dams (*n* = 11 per group) were mated with chow-fed males for first pregnancy. The dams were allowed to litter, and the first litter was culled after weaning. This first pregnancy ensured the mice were proven breeders. After a week, mice were remated for a second pregnancy and *day 1* of pregnancy was defined by the appearance of a plug. Dams were maintained on their respective experimental diets throughout both pregnancies and lactation. Litter sizes were standardized to three males and three females on *postnatal day 3*. Offspring groups \[control and maternal obesity (Mat-Ob)\] were weaned onto standard chow (RM1) at 21 days of age for the remainder of the study. Body weight and food intake were recorded weekly. At 8 wk of age, following an overnight fast, offspring were killed by rising CO~2~ concentration. Tissues were dissected, weighed, snap frozen, and stored at −80°C until use. Female offspring were assessed in this study.

### Dual-energy X-ray absorptiometry measurement of body composition. {#sec1-1-2}

Body composition analysis of offspring at 8 wk of age was performed by dual-energy X-ray absorptiometry (DEXA, Lunar PIXImus densitometer; GE Lunar, Madison, WI) immediately after killing.

### Serum analysis. {#sec1-1-3}

Fed plasma glucose measurement was obtained from tail blood using a blood glucose analyzer (OneTouch Ultra, LifeScan) between 9 and 10 a.m., the day before the end of the study. All analysis on fasted serum was carried out following an overnight 16-h fast. Fasted insulin was measured using a Mercodia insulin ELISA kit (Mercodia AB, Uppsala, Sweden). Fasted triglycerides, free fatty acid (FFA), high-density lipoprotein (HDL), and cholesterol were measured using enzymatic assays (Dade Behring, Siemens Healthcare, Deerfield, IL). Low-density lipoprotein (LDL) was calculated from cholesterol, HDL and triglyceride levels using the formula LDL = cholesterol − HDL − (triglycerides/2.2).

### Oxidative stress ELISA assays. {#sec1-1-4}

An 8-hydroxo-2-deoxy guanosine (8-OH-dG) EIA kit (StressMarq Biosciences no. SKT-120--96) was used to determine serum 8-OH-dG as a marker of DNA damage. Liver protein oxidation was measured using a 3-nitrotyrosine (3NT) ELISA kit (Abcam MitoSciences no. ab116691; Abcam, Cambridge, MA). Liver lipid peroxidation was measured using an OxiSelect 4-hydroxynonenal (4HNE) adduct ELISA kit (Cell Biolabs, no. STA-338). Mitochondrial complex I, II, and IV activities were measured using enzyme activity microassay kits (Abcam no. ab109721, no. ab109908, and no. ab109911, respectively) in isolated liver mitochondria (no. ab110170). All kits were used according to the manufacturers\' protocols.

### Western blot analysis. {#sec1-1-5}

The method has been described previously ([@B35]). In brief, liver protein lysates were standardized to a concentration of 2 mg/ml, and 40 μg total protein was resolved using SDS-PAGE. [Table 1](#T1){ref-type="table"} lists the primary antibodies used in this study. Antibodies were diluted in 1× TBS, 0.1% Tween 20 containing either 1% nonfat dehydrated milk or 5% BSA. Horseradish peroxidase-conjugated secondary antibodies \[anti-rabbit/mouse/goat antibody (Jackson ImmunoResearch, Stratech, Newmarket, UK)\] were used. Protein expression was quantified densitometrically using AlphaEase software (AlphaInnotech, San Leandro, CA).

###### 

Antibodies used in this study

  Antibody                      Source   Dilution   Company
  ----------------------------- -------- ---------- -----------------------------------------
  5-Lipoxygenase                Rabbit   1:1000     Cell Signaling, no. 3289
  Acetyl-CoA carboxylase        Rabbit   1:1000     Cell Signaling, no. 3676
  Akt1                          Mouse    1:1000     Cell Signaling, no. 2967
  Akt2                          Rabbit   1:5000     Cell Signaling, no. 2962
  ATGL                          Rabbit   1:1000     Cell Signaling, no. 2439
  Catalase                      Rabbit   1:10000    Abcam, no. ab1877
  COX4                          Rabbit   1:1000     Cell Signaling, no. 4844
  CuZnSOD                       Goat     1:20000    R&D Systems, no.AF3787
  CYP4A14                       Mouse    1:10000    Santa Cruz Biotechnology, no. sc-271983
  Cytochrome *c*                Mouse    1:1000     Abcam, no. ab13575
  eNOS                          Rabbit   1:1000     Cell Signaling, no. 9572
  Fatty acid synthase           Rabbit   1:10000    Cell Signaling, no. 3180
  G6Pase                        Goat     1:500      Santa Cruz Biotchnology, no. sc-27198
  Glutamate dehydrogenase 1/2   Rabbit   1:1000     Cell Signaling, no. 9828
  Glutathione reductase         Rabbit   1:1000     Abcam, no. ab16801
  GPx1                          Goat     1:2000     R&D Systems, no. AF3798
  GSK3α/β                       Mouse    1:200      Santa Cruz Biotechnology, no. sc-7291
  Heme oxygenase 1              Rabbit   1:2000     Abcam, no. ab13243
  iNOS                          Rabbit   1:1000     Cell Signaling, no.2977
  IRS1                          Rabbit   1:1000     Upstate (Merck Millipore), no. 06-248
  IRβ                           Rabbit   1:200      Santa Cruz Biotechnology, no. sc-711
  Lipoprotein lipase            Mouse    1:1000     Abcam, no. ab21356
  MnSOD                         Rabbit   1:10000    Upstate (Merck Millipore), no. 06-984
  NOX4                          Rabbit   1:500      Abcam no., no. ab60940
  p110β                         Rabbit   1:1000     Santa Cruz Biotechnology, no. sc-602
  p47-phox                      Goat     1:200      Santa Cruz Biotechnology, no. sc-23492
  p85α                          Rabbit   1:1000     Upstate (Merck Millipore), no. 06-195
  PEPCK                         Rabbit   1:1000     Santa Cruz Biotechnology, no. sc-32879
  Phospho-Akt (Ser-437)         Rabbit   1:1000     Cell Signalling, no. 4058
  Phospho-GSK3α/β (Ser-21/9)    Rabbit   1:1000     Cell Signaling, no. 9331
  Phospho-IRS1 (Tyr-608)        Rabbit   1:1000     Upstate (Merck Millipore), no. 09-432
  PKCζ                          Rabbit   1:1000     Santa Cruz Biotechnology, no. sc-216
  PPARα                         Rabbit   1:200      Santa Cruz Biotechnology, no. sc-9000
  PPARγ                         Rabbit   1:1000     Cell Signaling, no. 2435
  Pyruvate dehydrogenase        Rabbit   1:1000     Cell Signaling, no. 2784
  SREBP1                        Rabbit   1:200      Santa Cruz Biotechnology, no. sc-8984
  TNFα                          Rabbit   1:1000     Cell Signaling, no. 3707
  Xanthine oxidase              Rabbit   1:200      Santa Cruz Biotechnology, no. sc-20991

ATGL, adipose triglyceride lipase; COX4, cytochrome-*c* oxidase complex IV; CuZnSOD, copper/zinc superoxide dismutase; CYP4A14, cytochrome *P*-450 4A14; eNOS, endothelial nitric oxide synthase; G6Pase, glucose-6 phosphatase; GPx1, glutathione peroxidase-1; GSK3, glycogen synthetase kinase; iNOS, inducible nitric oxide synthase; IRS1, insulin receptor substrate-1; IRβ, insulin receptor β; MnSOD, manganese superoxide dismutase; NOX4, NADPH oxidase 4; PEPCK, phosphoenolpyruvate carboxykinase; PPAR, peroxisome proliferator activator receptor; SREBP1, sterol regulatory element-binding protein 1.

### Liver glycogen assay. {#sec1-1-6}

An amyloglucosidase assay was used to determine glycogen content of the liver ([@B31]). Frozen liver tissue (100 mg) was homogenized in 1 ml of ice-cold deionized water. Homogenate (100 μl) was incubated with 100 μl 50 mM acetate buffer (pH 4.5), with or without 70 units amyloglucosidase enzyme and 200 μl deionized water at 55°C for 10 min. 300 mM zinc sulfate (300 μl) and 300 mM barium hydroxide (300 μl) were added, and samples were mixed and centrifuged at 2,000 *g* for 10 min to deproteinize the samples. Supernatants were collected, and glucose concentrations were analyzed using a YSI 2300 STAT PLUS glucose analyzer (Yellow Springs Instruments Life Sciences, Yellow Springs, Ohio). Glycogen content relative to tissue weight was calculated as the glucose derived from enzymatic digestion by subtraction of free glucose (homogenate incubated without enzyme) from the total amount of glucose present in the liver homogenate (homogenate incubated with enzyme).

### Liver lipid assay. {#sec1-1-7}

Liver lipids were extracted, according to a modified Folch method ([@B12]). Frozen liver tissue (100 mg) was thoroughly homogenized with 1 ml of a 2:1 ratio choloroform:methanol mixture (Sigma-Aldrich, Dorset, UK). Deionized water (200 μl) was then added to the mix, vortexed, and shaken for 10 min. Samples were centrifuged for 10 min at 16,100 *g* to generate a distinct organic and aqueous phase. The lower organic phase (500 μl) was collected into a preweighed glass tube and dried using a rotary evaporator for 2 h at 37°C, and the remaining lipid content was weighed.

### Liver histology. {#sec1-1-8}

Liver sections were stained with Oil Red O for lipid content, according to a standard protocol. Briefly, liver fixed in 10% formalin were processed, paraffin-embedded, cut into 7-μm sections, and immersed in 30% sucrose solution overnight. Sections were rinsed in 60% isopropanol, immersed in freshly prepared Oil Red O solution for 15 min (Sigma-Aldrich, UK), rinsed again in 60% ispopropanol, and nuclei counterstained in Mayer\'s hemotoxylin. Images were captured on an inverted light microscope (Olympus BX41; Olympus, Southend-on-Sea, UK). Analysis was carried out using Adobe Photoshop Elements (Adobe Systems Software, Dublin, Ireland) on two fields of view from two sections per sample (*n* = 7 per group). Lipid droplets (red) were selected using the magic wand tool and quantified as a percentage of positively stained pixels in the field of view.

### Statistical analysis. {#sec1-1-9}

Data were analyzed from one female offspring per litter; therefore, *n* refers to the number of litters per group. Data were analyzed by unpaired Student\'s *t*-test using Prism 5 (GraphPad, La Jolla, CA) unless stated otherwise. Protein expression data are presented as a percentage of mean expression of control group ± SE. All data are shown as means ± SE. For all data, *P* \< 0.05 was considered statistically significant.

RESULTS {#sec2}
=======

 {#sec2-1}

### Offspring phenotype. {#sec2-1-1}

Maternal diet did not affect offspring weight on *postnatal day 3* (Control 1.76 ± 0.06 g vs. Mat-Ob 1.63 ± 0.12 g, *n* = 11) or litter size (Control 7.6 ± 0.3 vs. Mat-Ob 6.0 ± 0.7, *n* = 11). At 8 wk of age, body weight, body composition, and liver weight were not significantly different between control and Mat-Ob offspring ([Table 2](#T2){ref-type="table"}). Cumulative food intake between weaning and *week 8* was similar between the two experimental groups (Control 107.6 ± 4.0 g vs. Mat-Ob 111.8 ± 3.4 g, *n* = 8 and *n* = 7, respectively). Levels of glucose, triglycerides, and FFA did not differ significantly between the two offspring groups at this age. Fasting total cholesterol and HDL cholesterol were significantly reduced in the Mat-Ob offspring compared with controls (*P* \< 0.05) ([Table 3](#T3){ref-type="table"}). Fasting insulin levels, however, were significantly elevated in the Mat-Ob group compared with controls ([Fig. 1*A*](#F1){ref-type="fig"}, *P* \< 0.05).

###### 

Body composition of 8-wk-old females

                               Control        Mat-Ob
  ---------------------------- -------------- --------------
  Total body weight, g         20.85 ± 0.98   19.16 ± 0.78
  Fat mass, g                  3.24 ± 0.17    3.20 ± 0.26
  Lean mass, g                 15.04 ± 0.12   14.77 ± 0.61
  Bone mass density, g/cm^2^   0.04 ± 0.00    0.06 ± 0.02
  \% Fat mass                  17.74 ± 0.63   17.83 ± 0.78
  \% Lean mass                 83.03 ± 0.69   82.08 ± 0.68
  Liver weight, g              1.12 ± 0.04    0.98 ± 0.06
  \% Liver weight              5.37 ± 0.04    4.90 ± 0.08

Data are presented as means ± SE; *n* = 6 per group. Mat-Ob, maternal obesity.

###### 

Serum profile of 8-wk-old females

                              Control       Mat-Ob
  --------------------------- ------------- ----------------------------------------------
  Total cholesterol, mmol/l   2.55 ± 0.12   1.93 ± 0.07[\*](#TF3-1){ref-type="table-fn"}
  HDL cholesterol, mmol/l     0.99 ± 0.04   0.85 ± 0.04[\*](#TF3-1){ref-type="table-fn"}
  LDL cholesterol, mmol/l     0.94 ± 0.07   0.76 ± 0.06
  Triglycerides, mmol/l       0.75 ± 0.05   0.70 ± 0.11
  FFA, mmol/l                 1.03 ± 0.08   0.87 ± 0.05
  Glucose (fed), mmol/l       9.5 ± 1.1     10.2 ± 1.1
  Glucose (fasted), mmol/l    6.7 ± 0.3     5.9 ± 0.6

Data are presented as means ± SE; *n* = 6 per group,

*P* \< 0.05. HDL, high-density lipoprotein; LDL, low-density lipoprotein; FFA, free fatty acid.

![Insulin and oxidative stress markers. *A*: fasting serum insulin concentration. *B*: serum 8-hydroxy-2-deoxy guanosine (8-OH-dG) concentration. *C*: liver 3-nitrotyrosine (3NT) concentration. *D*: liver 4-hydroxynonenal (4HNE) concentration. *E*: protein levels of liver tumor necrosis factor-α (TNF-α). Data are presented as means ± SE for control (white bar) and maternal obesity (Mat-Ob) (gray bar) offspring. *n* = 6--8 per group. \**P* \< 0.05, \*\**P* \< 0.01.](zh60141484780001){#F1}

### Liver insulin signaling. {#sec2-1-2}

We investigated whether the hyperinsulinemia may be related to disrupted liver insulin signaling protein expression. However, no differences were detected in key hepatic insulin signaling molecules in the offspring in response to maternal obesity at 8 wk of age ([Table 4](#T4){ref-type="table"}).

###### 

Insulin signaling protein expression in 8-wk-old female liver tissue

  Expression, % mean control   Control    Mat-Ob
  ---------------------------- ---------- ----------
  IRβ                          100 ± 3    102 ± 4
  IRS1                         100 ± 15   120 ± 15
  p-IRS1(Ser-307)              100 ± 16   109 ± 15
  Akt1                         100 ± 10   91 ± 11
  Akt2                         100 ± 4    99 ± 5
  p-Akt(Ser-473)               100 ± 23   95 ± 30
  p110β                        100 ± 18   110 ± 11
  p85α                         100 ± 4    92 ± 7
  PKCζ                         100 ± 4    103 ± 5

Data are presented as means ± SE; *n* = 6 per group.

### Oxidative stress damage. {#sec2-1-3}

Serum 8-OH-dG and liver 3NT, as markers of DNA and protein oxidative damage, respectively, were significantly increased in Mat-Ob offspring ([Fig. 1](#F1){ref-type="fig"}, *B* and *C*, *P* \< 0.01 and *P* \< 0.05, respectively). Liver 4HNE, a marker of lipid oxidation, remained unchanged between the two experimental groups at this age ([Fig. 1*D*](#F1){ref-type="fig"}). Liver TNF-α was significantly elevated in the Mat-Ob offspring compared with controls ([Fig. 1*E*](#F1){ref-type="fig"}, *P* \< 0.05).

### Oxidative homeostasis. {#sec2-1-4}

Proteins involved in oxidative homeostasis were studied as possible contributors to increased oxidative stress. Livers of 8-wk-old Mat-Ob females had significantly lower NADPH oxidase 4 (NOX4) compared with controls ([Fig. 2*A*](#F2){ref-type="fig"}, *P* \< 0.01). There was also a significant reduction in the antioxidant enzyme glutathione peroxidase-1 (GPx1) (*P* \< 0.001) and a significant increase in catalase levels (*P* \< 0.05) in the Mat-Ob group compared with controls ([Fig. 2*B*](#F2){ref-type="fig"}). No significant differences were observed in other proteins studied.

![Oxidative homeostasis. *A*: protein levels of oxidative and nitrosative enzymes. eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; XO, xanthine oxidase; NOX4, NADPH oxidase 4. *B*: protein levels of antioxidant enzymes. MnSOD, manganese superoxide dismutase; GPx1, glutathione peroxidase-1; GR, glutathione reductase; CuZnSOD, copper/zinc superoxide dismutase; HO1, heme oxygenase-1. *C*: mitochondrial complex activities. *D*: protein levels of mitochondrial enzymes. COX4, cytochrome-*c* oxidase complex IV; Cyt *c*, cytochrome *c*; glutamate DH, glutamate dehydrogenase. Data are presented as means ± SE for control (white bar) and Mat-Ob (gray bar) offspring. *n* = 6--8 per group. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](zh60141484780002){#F2}

Uncoupling of mitochondrial oxidative respiration can also be a source of free radicals. Liver mitochondrial complex I and II activities were significantly increased in Mat-Ob offspring compared with controls ([Fig. 2*C*](#F2){ref-type="fig"}, *P* \< 0.001 and *P* \< 0.05, respectively). Although complex IV expression and activities were not different, we observed a significant reduction in the expression of cytochrome *c*, the complex III-IV electron shuttle, in the offspring of diet-induced obese dams compared with controls ([Fig. 2*D*](#F2){ref-type="fig"}, *P* \< 0.01). Glutamate dehydrogenase (GDH), a marker of intact mitochondria, was elevated in this group ([Fig. 2*D*](#F2){ref-type="fig"}, *P* \< 0.05).

### Liver lipid metabolism. {#sec2-1-5}

We measured the levels of proteins involved in lipogenesis and lipolysis to identify possible changes in liver lipid homeostasis. PPARγ was significantly upregulated (*P* \< 0.05), acetyl co-A carboxylase (ACC) protein levels were increased by 49% (*P* = 0.08) ([Fig. 3*A*](#F3){ref-type="fig"}), and there was a significant reduction in liver triglyceride lipase (ATGL) in Mat-Ob offspring compared with controls (*P* \< 0.05) ([Fig. 3*B*](#F3){ref-type="fig"}). No significant differences were found in other proteins studied. These changes in lipid homeostasis were associated with increased total lipid content in Mat-Ob livers compared with the control group at 8 wk of age, as determined by both lipid assay and histological lipid content analysis (*P* \< 0.05 and 0.001, respectively, [Fig. 3](#F3){ref-type="fig"}, *C--E*).

![Liver lipid metabolism. *A*: protein levels of lipogenic enzymes. ACC, acetyl coA carboxylase; PDH, pyruvate dehydrogenase; PPARγ, peroxisome proliferator activator receptor γ; FAS, fatty acid synthase; SREBP1, sterol regulatory element-binding protein 1. *B*: protein levels of lipolytic enzymes. PPARα, peroxisome proliferator activator receptor α; LPL, lipoprotein lipase; ATGL, adipose triglyceride lipase; 5-LO, 5-lipoxygenase; CYP4A14, cytochrome *P*-450 4A14. *C*: total liver lipid content determined from 100 mg liver tissue. *D*: representative Oil-red-O (ORO) and hematoxylin-and-eosin (H&E) histology images. Scale bar is 50 μm. *E*: quantification of lipid droplet staining. Data are presented as means ± SE for control (white bar) and Mat-Ob (gray bar) offspring. *n* = 6--8 per group; \**P* \< 0.05, \*\*\**P* \< 0.001.](zh60141484780003){#F3}

### Liver glycogen metabolism. {#sec2-1-6}

Total fasted liver glycogen content in the Mat-Ob group was significantly reduced compared with the control group ([Fig. 4*A*](#F4){ref-type="fig"}, *P* \< 0.05). Glycogen synthase kinase-3 (GSK-3) α and β protein levels were similar between the two experimental groups, and their phosphorylation levels were also not different ([Fig. 4*B*](#F4){ref-type="fig"}). The levels of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), key gluconeogenic enzymes, were reduced in expression in the Mat-Ob group compared with controls ([Fig. 4*C*](#F4){ref-type="fig"}, *P* = 0.08 and 0.07, respectively).

![Liver glycogen metabolism. *A*: liver glycogen content. *B*: protein levels of total glycogen synthase kinase-3 isoforms and their phosphorylation levels. *C*: protein levels of gluconeogenic enzymes. PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6 phosphatase. Data are presented as means ± SE for control (white bar) and Mat-Ob (gray bar) offspring. *n* = 6--8 per group, \**P* \< 0.05.](zh60141484780004){#F4}

### Liver protein content. {#sec2-1-7}

There was a small, but statistically significant, reduction in total liver protein content in female Mat-Ob offspring compared with controls (Control 0.28 ± 0.01 vs. Mat-Ob 0.25 ± 0.00 mg protein/mg tissue, *n* = 6 and *n* = 5 respectively, *P* \< 0.05).

DISCUSSION {#sec3}
==========

Obesity during pregnancy is a growing problem in both the developed and developing world. It is now evident that maternal obesity during pregnancy increases the risk of metabolic diseases in the offspring, including impaired glucose tolerance, insulin resistance, obesity, and NAFLD. The mechanisms underlying this programming are not well understood, and the close interrelationships between these pathologies make it difficult to dissect out primary metabolic defects. We rationalized, therefore, that to identify programming mechanisms for NAFLD, we would need to study offspring at an early time point, prior to the development of glucose intolerance and obesity.

We found that at 8 wk of age, there were no differences in body weight or adiposity between control and Mat-Ob offspring. Therefore, any metabolic differences can be attributed to differential programming of metabolic tissues. Hyperinsulinemia in Mat-Ob offspring before the onset of obesity indicate that they were insulin-resistant at this age. This is likely to be driven by insulin resistance in adipose tissue ([@B11]), as there were no differences in the hepatic expression of key insulin signaling proteins measured at this age, suggesting the liver is insulin-sensitive. The significance of reduced circulating cholesterol levels in Mat-Ob offspring is unclear. However, there is little evidence to suggest a link between serum cholesterol levels and hepatic fat deposition. One study has reported an association between hepatic steatosis and reduced HDL cholesterol levels in type 2 diabetic patients ([@B37]), whereas another study reported that the association was rendered nonsignificant after correction for insulin resistance ([@B17]), suggesting insulin resistance as a greater contributory factor to hepatic lipid deposition.

We suggest that hyperinsulinemia in Mat-Ob offspring, driven by peripheral insulin resistance, promotes the transcriptional upregulation of hepatic genes, including PPARγ, to promote de novo lipogenesis in the liver. Hormonal regulation of PPARγ activity has been previously demonstrated in cases where PPARγ activity was stimulated by insulin treatment ([@B40], [@B41]), and furthermore, its overexpression led to hepatic steatosis ([@B42]). As well as stimulating lipogenesis, insulin promotes lipid accumulation by inhibiting lipolysis. In the offspring of diet-induced obese dams, reduced expression of ATGL, the enzyme initiating the first step of lipid hydrolysis, is likely to contribute to hepatic lipid accumulation ([@B14]). Insulin has been reported to downregulate the transcription of ATGL via the mTOR pathway in mammalian adipocytes ([@B6]). Thus, the early development of peripheral insulin resistance in offspring of diet-induced obese dams may be a driver of hepatic triglyceride accumulation by regulating genes that are predominantly expressed in adipose tissue under normal conditions.

Hepatic insulin sensitivity in offspring exposed to maternal obesity declines by 12 wk of age, at which time the expression of key components of the insulin signaling pathway, including the insulin receptor and IRS1, is reduced ([@B1], [@B21], [@B28]); this could further exacerbate lipid accumulation and liver damage. Because we observed elevated markers of oxidative damage both in the circulation and in the liver, we investigated further whether oxidative dysregulation could contribute to NAFLD and the later development of insulin resistance; this confirmed an impaired hepatic antioxidant capacity through reduced GPx1 expression. Oxidative stress following HFD feeding has been observed to precede insulin resistance ([@B22]), the development of which can be prevented by antioxidant supplementation in rodents ([@B5], [@B7], [@B16]). Inflammation has been observed as early as the blastocyst stage in programming models ([@B34]). Thus, the raised hepatic TNF-α observed in this study provides further evidence for a state of enhanced oxidative stress. Increased oxidative damage markers 8-OH-dG and 4HNE have also been reported in livers of macaque fetuses exposed to a HFD in utero ([@B23]).

It is important to note that differences in animal models in terms of dietary composition, timing, and length of exposure confound the development of a single mechanistic model of programming. The majority of studies published to date investigating the hepatic effects of maternal overnutrition have utilized a HFD. In this study, dams were fed a high-fat, high-sugar diet to better reflect Western obesogenic environments. Differences in the metabolic responses of rodents fed a HFD vs. "cafeteria" Western diet have been previously noted, although both dietary challenges can induce obesity and hepatosteatosis, cafeteria-fed rats display increased inflammation in fat and liver tissue ([@B32]). Therefore, specificity in programming mechanisms from different dietary challenges cannot be dismissed and require further study. Nonetheless, our current findings are consistent with oxidative stress as an early mechanism through which offspring of diet-induced obese mothers are predisposed to NAFLD. The current findings suggest that the chronic oxidative damage resulting from maternal high-fat, high-sugar feeding is a programmed response independent of increased adiposity, and when coupled with hepatic lipid deposition, can contribute to insulin resistance and progressive hepatic steatosis and liver damage.

In our model of maternal diet-induced obesity, mitochondrial dysfunction is likely to be a source of ROS. While Bruce et al. ([@B3]) have previously reported reduced mitochondrial complex I, II/III, and IV activity in the livers of 15-wk-old offspring of HFD-fed dams, at 8 wk of age, we have observed here that Mat-Ob offspring complex I and II activities were increased along with reduced expression of the downstream electron carrier cytochrome *c*. This uncoupling of activity across the electron transport chain would likely result in increased electron leakage and free radical generation. Furthermore, expression of glutamate dehydrogenase---an enzyme abundantly expressed in liver mitochondria---was increased in Mat-Ob offspring. Serum levels of GDH are used as a marker of liver injury ([@B27]). The hepatic elevation in response to maternal diet-induced obesity may suggest compensatory mitochondrial proliferation in response to impaired function or hepatocyte necrosis (although the latter was not investigated in the present study). Thus, we hypothesize that mitochondrial dysfunction coupled with reduced antioxidant capacity contributes to the pro-oxidative environment at an early age. Catalase is an antioxidant enzyme known to be upregulated in response to oxidative stress ([@B36]). Therefore, the elevation of this protein in the Mat-Ob livers suggests a progressive compensatory response to ROS exposure. There is evidence to suggest a redox-centered pathogenic theory of NAFLD, where the redox state/ROS can modulate lipid metabolism, as well as insulin sensitivity ([@B33]). Furthermore, increased mitochondrial metabolism and complex III-generated ROS was found to induce PPARγ activity and adipocyte differentiation ([@B38]). The free radical biology of PPARγ in hepatocytes merits further investigation but suggests a further role for oxidative dysregulation in the underlying pathogenesis of NAFLD.

We observed reduced hepatic glycogen and protein in Mat-Ob offspring. This has also been observed in rats fed a HFD, where an inverse relationship between liver triglyceride and glycogen content was associated with insulin resistance ([@B18]), suggesting this is a compensatory response for the maintenance of hepatocyte integrity and function. Reduced lipolysis via ATGL and reduced gluconeogenesis via PEPCK and G6Pase suggests that glycogen is the predominant source of energy in the Mat-Ob offspring.

Perspectives and Significance {#sec3-1}
-----------------------------

In conclusion, our data provide evidence that exposure to an obesogenic environment during early developmental stages can prime offspring to increased susceptibility to nonalcoholic fatty liver disease. We propose a model in which the offspring of diet-induced obese dams develop early hyperinsulinemia from peripheral insulin resistance, thereby stimulating hepatic lipid deposition. Uncoupled mitochondrial respiration and oxidative stress in the liver further modulate lipid metabolism and contribute to the onset of hepatic insulin resistance, exacerbating hepatic steatosis with age. Hyperinsulinemia and reactive oxygen species may, therefore, present very early therapeutic targets for the prevention of NAFLD in susceptible individuals. This research emphasizes the importance of a balanced diet during pregnancy and lactation for the long-term health of subsequent generations.
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